Neurocrine Biosciences, Inc. will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief Executive Officer Kyle Gano and Chief Medical Officer ...
A new national survey of Canadian adults reveals significant gaps in understanding of shingles risk factors and a lack of concern among those most at risk of the viral infection. The survey also found ...
Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE:GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...
2d
NEW YORK, NY / ACCESS Newswire / March 12, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...
Insider Monkey on MSN11d
Is GSK plc (GSK) The Best Immunology Stock To Buy Now?GSK plc (NYSE:GSK) has made immunology a core therapeutic focus alongside infectious diseases, HIV, and oncology, investing ...
GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
GlaxoSmithKline's head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics. Hoos is leaving GSK after nine ...
Hesham Abdullah, GSK's Senior Vice President, Global Head Oncology R&D, stated, "This acquisition adds to GSK's growing pipeline of targeted therapeutics for cancers originating in the ...
Dr. Kruger is an expert in cancer biology and epigenetics, having led research and development at GlaxoSmithKline (GSK) and biotechnology corporations. Dr. Knight worked at GSK for over 25 years ...
LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...
One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback